ArticleChest2020
Outcomes of Pulmonary Arterial Hypertension Are Improved in a Specialty Care Center.
Article in Chest, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Navigating the Complexities of Pulmonary Hypertension Care: Unique Challenges in PAH Management.Pulmonary circulation · 2026Review
- Quality of Pulmonary Hypertension Care Within Expert PH Centers: Patient and Provider Perspectives From a Multi-Site Qualitative Study.Pulmonary circulation · 2026Article
- Poverty and Social Deprivation in Patients With Pulmonary Arterial Hypertension-A PHAR Analysis.Pulmonary circulation · 2026Article
- Clinical Updates in Pulmonary Hypertension.Reviews in cardiovascular medicine · 2026Review
- Male Sex Is Associated With Severe Pulmonary Hypertension and Worse Outcome in Chronic Obstructive Pulmonary Disease Patients Referred for Right Heart Catheterization.Pulmonary circulation · 2026Article
- Insurance and Treatment Patterns in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry.Annals of the American Thoracic Society · 2026Article
- Provider networks for pulmonary hypertension in Massachusetts: implications for improving referrals to expert care.Annals of the American Thoracic Society · 2026Article
- Pulmonary Arterial Hypertension: Recognition and Management in Primary and Acute Care Settings.Cureus · 2025Review
- Gaps in access to pulmonary hypertension care and opportunities for improvement: a multi-site qualitative study.BMC pulmonary medicine · 2025Article
- Factors Associated with Referral to Expert Providers among Patients with Pulmonary Hypertension.Annals of the American Thoracic Society · 2025Article
- Pulmonary Hypertension Care Delivery in the United States: Is It Time to Get with the Guidelines?American journal of respiratory and critical care medicine · 2025Article
- Assessing the clinical benefit, safety, and patient-reported outcomes with the use of the PAHcare™ digital platform in pulmonary arterial hypertension: a pilot study.Frontiers in public health · 2024Article
- Omics and Extreme Phenotyping Reveal Longitudinal Association Between Left Atrial Size and Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension.Journal of the American Heart Association · 2023Article
- Organization of pulmonary hypertension care in non-expert care settings: Lessons learned from a multi-site study.Health services research · 2023Article
- Are Guideline-recommended Risk Classification Schemes in Pulmonary Hypertension Adequately Robust to Guide the Real-world Setting?Balkan medical journal · 2023Article
- Association Between Copayment and Adherence to Medications for Pulmonary Arterial Hypertension.Journal of the American Heart Association · 2022Article
- Where's the Easy Button? The Many Barriers to Care for Patients With Pulmonary Arterial Hypertension.Journal of the American Heart Association · 2022Article
- Improved hospitalization rates in a specialty center for heart failure with preserved ejection fraction and pulmonary hypertension.Pulmonary circulation · 2022Article
- Cardiovascular Diseases That Have Emerged From the Darkness.Journal of the American Heart Association · 2021Article
- Evaluation, Diagnosis, and Classification of Pulmonary Hypertension.Methodist DeBakey cardiovascular journal · 2021Review
Corrections and comments
- Commented on by
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundPulmonary arterial hypertension (PAH) is characterized by elevated pulmonary arterial pressures and is managed by vasodilator therapies. Current guidelines encourage PAH management in specialty care centers (SCCs), but evidence is sparse regarding improvement in clinical outcomes and correlation to vasodilator use with referral. RESEARCH QUESTION: Is PAH management at SCCs associated with improved clinical outcomes? STUDY DESIGNAND
methodsA single-center, retrospective study was performed at the University of Pittsburgh Medical Center (UPMC; overseeing 40 hospitals). Patients with PAH were identified between 2008 and 2018 and classified into an SCC or non-SCC cohort. Cox proportional hazard modeling was done to compare for all-cause mortality, as was negative binomial regression modeling for hospitalizations. Vasodilator therapy was included to adjust outcomes.
resultsOf 580 patients with PAH at UPMC, 455 (78%) were treated at the SCC, comprising a younger (58.8 vs 64.8 years; P < .001) and more often female (68.4% vs 51.2%; P < .001) population with more comorbidities without differences in race or income. SCC patients demonstrated improved survival (hazard ratio, 0.68; P = .012) and fewer hospitalizations (incidence ratio, 0.54; P < .001), and provided more frequent disease monitoring. Early patient referral to SCC (< 6 months from time of diagnosis) was associated with improved outcomes compared with non-SCC patients. SCC patients were more frequently prescribed vasodilators (P < .001) and carried more diagnostic PAH coding (P < .001). Vasodilators were associated with improved outcomes irrespective of location but without statistical significance when comparing between locations (P > .05).
interpretationThe UPMC SCC demonstrated improved outcomes in mortality and hospitalizations. The SCC benefit was multifactorial, with more frequent vasodilator therapy and disease monitoring. These findings provide robust evidence for early and regular referral of patients with PAH to SCCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.